84th Session of the Council

por Abragam, Anatole, Boyer, M, De Benedetti, C
Publicado 1987

84ème Session du Conseil

por Abragam, Anatole, Boyer, M, De Benedetti, C
Publicado 1987

Compte rendu de l'entretien du 12.10.76

por BOYER, M F, CHAINTREUIL, MM R, GEORGIJEVIC, M, PASQUALI, J
Publicado 1976

Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours.

por Boyer, M. J., Barnard, M., Hedley, D. W., Tannock, I. F.
Publicado 1993

Compte rendu de l’entretien du 29.11.76

por BOYER, M F, CHAINTREUIL, MM R, GEORGIJEVIC, M, MARY, M, PASQUALI, J
Publicado 1976

Promoting patient participation in the cancer consultation: evaluation of a prompt sheet and coaching in question-asking

por Brown, R, Butow, P N, Boyer, M J, Tattersall, M H N
Publicado 1999

Mechanism of eosinophilia. IV. The pulmonary lesion resulting from intravenous injection of Trichinella spiralis.

por Boyer, M. H., Spry, C. J., Beeson, P. B., Sheldon, W. H.
Publicado 1971

pH dependent cytotoxicity of N-dodecylimidazole: a compound that acquires detergent properties under acidic conditions.

por Boyer, M. J., Horn, I., Firestone, R. A., Steele-Norwood, D., Tannock, I. F.
Publicado 1993

P1.12-02 The Impact of COVID-19 on Quality of Care for Lung Cancer - Analyses of Prospective Clinical Data from The EnRICH Cohort

por Brown, B., Young, J., Galpin, K., Brown, C., Boyer, M., Chin, V., Hogg, P., Simes, J.
Publicado 2022

Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer

por Stockler, M R, Tattersall, M H N, Boyer, M J, Clarke, S J, Beale, P J, Simes, R J
Publicado 2006

A phase II trial of paclitaxel and epirubicin in advanced breast cancer

por Rischin, D, Smith, J, Millward, M, Lewis, C, Boyer, M, Richardson, G, Toner, G, Gurney, H, McKendrick, J
Publicado 2000

Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experi...

por Vardy, J, Engelhardt, K, Cox, K, Jacquet, J, McDade, A, Boyer, M, Beale, P, Stockler, M, Loneragan, R, Dennien, B, Waugh, R, Clarke, S J
Publicado 2004

Performances of Anode-resistive Micromegas for HL-LHC

por Manjarres, J., Alexopoulos, T., Attié, D., Boyer, M., Derré, J., Fanourakis, G., Ferrer-Ribas, E., Galán, J., Gazis, E., Geralis, T., Giganon, A., Giomataris, I., Herlant, S., Jeanneau, F., Schune, Ph., Titov, M., Tsipolitis, G.
Publicado 2012

The ASACUSA Micromegas Tracker: A cylindrical, bulk Micromegas detector for antimatter research

por Radics, B, Nagata, Y, Yamazaki, Y, Ishikawa, S, Kuroda, N, Matsuda, Y, Anfreville, M, Aune, S, Boyer, M, Chateau, F, Combet, M, Granelli, R, Legou, P, Mandjavidze, I, Procureur, S, Riallot, M, Vallage, B, Vandenbroucke, M
Publicado 2015

Performances and ageing study of resistive-anodes Micromegas detectors for HL-LHC environment

por Jeanneau, Fabien, Alexopoulos, T., Attie, D., Boyer, M., Derre, J., Fanourakis, G., Ferrer-Ribas, E., Galan, J., Gazis, E., Geralis, T., Giganon, A., Giomataris, I., Herlant, S., Manjarres, J., Ntomari, E., Schune, P., Titov, M., Tsipolitis, G., Wang, W.
Publicado 2012

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

por Mahon, K L, Qu, W, Devaney, J, Paul, C, Castillo, L, Wykes, R J, Chatfield, M D, Boyer, M J, Stockler, M R, Marx, G, Gurney, H, Mallesara, G, Molloy, P L, Horvath, L G, Clark, S J
Publicado 2014

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

por Lin, H-M, Castillo, L, Mahon, K L, Chiam, K, Lee, B Y, Nguyen, Q, Boyer, M J, Stockler, M R, Pavlakis, N, Marx, G, Mallesara, G, Gurney, H, Clark, S J, Swarbrick, A, Daly, R J, Horvath, L G
Publicado 2014

Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide

por Cebon, J, Findlay, M, Hargreaves, C, Stockler, M, Thompson, P, Boyer, M, Roberts, S, Poon, A, Scott, A M, Kalff, V, Garas, G, Dowling, A, Crawford, D, Ring, J, Basser, R, Strickland, A, Macdonald, G, Green, M, Nowak, A, Dickman, B, Dhillon, H, Gebski, V
Publicado 2007

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

por Mahon, K L, Lin, H-M, Castillo, L, Lee, B Y, Lee-Ng, M, Chatfield, M D, Chiam, K, Breit, S N, Brown, D A, Molloy, M P, Marx, G M, Pavlakis, N, Boyer, M J, Stockler, M R, Daly, R J, Henshall, S M, Horvath, L G
Publicado 2015

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

por Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D.-W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K.
Publicado 2017